scispace - formally typeset
C

Christopher R. Bilder

Researcher at University of Nebraska–Lincoln

Publications -  57
Citations -  1991

Christopher R. Bilder is an academic researcher from University of Nebraska–Lincoln. The author has contributed to research in topics: Group testing & Regression analysis. The author has an hindex of 21, co-authored 55 publications receiving 1724 citations. Previous affiliations of Christopher R. Bilder include Oklahoma State University–Stillwater & Kansas State University.

Papers
More filters
Journal ArticleDOI

An Introduction to Categorical Data Analysis

TL;DR: Bilder and Tebbs review An Introduction to Categorical Data Analysis (2nd ed.) by Alan Agresti as discussed by the authors, which is a good starting point for this paper.
Journal ArticleDOI

Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources.

TL;DR: When the incidence rate of SARS-CoV-2 infection is 10% or less, group testing will result in the saving of reagents and personnel time with an overall increase in testing capability of at least 69%.
Journal ArticleDOI

Informative Dorfman screening.

TL;DR: This article uses individuals’ risk probabilities to formulate new informative decoding algorithms that implement Dorfman retesting in a heterogeneous population, and introduces the concept of “thresholding” to classify individuals as “high” or “low risk,” so that separate, risk‐specific algorithms may be used, while simultaneously identifying pool sizes that minimize the expected number of tests.
Book

Analysis of Categorical Data with R

TL;DR: Analyzing a Binary Response, Part 1: Introduction One binary variable Two binary variables, Part 2: Regression Models Linear regression models Logistic regression models Generalized linear models Analyzing a Multicategory Response Multinomial probability distribution.
Posted ContentDOI

Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources.

TL;DR: Group testing will result in the saving of reagents and personnel time with an overall increase in testing capability of at least 69% when the incidence rate of SARS-CoV-2 infection is 10% or less.